Trial Profile
hzVSF-v13 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics After Intravenous and Subcutaneous Administration in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Burfiralimab (Primary) ; Burfiralimab (Primary)
- Indications Alcoholic hepatitis; COVID-19 pneumonia; Hepatitis B; Non-alcoholic steatohepatitis; Psoriasis; Scleroderma
- Focus Adverse reactions
- Sponsors ImmuneMed
- 14 Feb 2024 Status changed from recruiting to completed.
- 28 Dec 2020 New trial record